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Abstract
Background: Leg edema is a common adverse effect of dihydropyridine Calcium Channel Blockers (CCB) that may
need dose reduction or drug withdrawal, adversely affecting the antihypertensive efficacy. Leg edema is reported
to occur less often with (S)-amlodipine compared to conventional racemic amlodipine. We aimed to find the
incidence of leg edema as a primary outcome and antihypertensive efficacy with (S)-amlodipine compared to
conventional amlodipine.
Methods: This prospective, double-blind, controlled clinical trial randomized 172 hypertensive patients, not
controlled on beta-blockers (BB) and angiotensin converting enzyme inhibitors/angiotensin receptor blockers
(ACEI/ARB), to either conventional amlodipine (5–10 mg; n = 86) or (S)-amlodipine (2.5–5 mg; n = 86), while
continuing their previous anti-hypertensive medications. Sample was sufficient to find a difference in edema
between the interventions with 80 % power at 5 % significance level. Intension to treat analysis (ITT) for safety data and
per protocol analysis for efficacy data was performed. Fischer’s exact test was applied to observe difference between
responder rates and proportions of subjects having peripheral edema in the two groups. Pitting edema test scores
were compared using Mann–Whitney test.
Results: Altogether 146 patients (amlodipine, n = 76 and (S)-amlodipine, n = 70) completed 120 days treatment.
Demographic variables and treatment adherence were comparable in the two groups. Incidence of new edema
after randomization was 31.40 % in test group and 46.51 % in control group [p = 0.03; absolute risk reduction
(ARR) = 15.1 %; Number Needed to Treat (NNT) = 7, ITT analysis]. Pitting edema score and patient rated edema
score increased significantly in the control compared to test group (p = 0.038 and 0.036 respectively) after treatment
period. Edema scores increased significantly in the control group from baseline (p < 0.0001). Responders in blood
pressure were 98.57 % in test and 98.68 % in control group. Most common adverse events (AE) were pitting edema
and increased urinary frequency. Incidence of all AEs other than edema was similar in both groups. Two serious AEs
occurred unrelated to therapy. Biochemical and ECG parameters in the two groups were comparable.
Conclusions: In hypertensive patients not controlled on prior BB and ACEI/ARB therapy, addition of (S)-amlodipine
besylate at half the dose of conventional amlodipine provides better tolerability with reduced incidence of peripheral
edema, and equal antihypertensive efficacy compared to amlodipine given at usual doses.
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Background
Amlodipine is a calcium channel blocker (CCB) of the
third generation dihydropyridine CCB group, used as
monotherapy or in combination, for treatment of hyper-
tension and angina [1–4]. Peripheral edema, particularly
of the lower limbs, is a common adverse effect of dihy-
dropyridine CCB. This might lead to dose reduction or
drug withdrawal, adversely affecting the antihypertensive
efficacy [5–7]. The degree of peripheral edema that oc-
curs with CCB treatment is dependent on the dose and
the drug used [8–10].
Reported rates of peripheral edema with CCBs varies
widely because of the drug and dose-dependent nature,
ranging from 5 to even 70 % with high doses [5, 9–12].
The incidence of edema reported in the literature can
also be dependent on the method of edema assessment
in the clinical trials [13, 14].
Racemic or conventional amlodipine contains (R)-and
(S)-amlodipine isomers in a 1:1 ratio, but (S)-amlodipine
has been shown to be the only active isomer of amlodipine
which has calcium channel blocking activity, providing all
the therapeutic effects [15]. Therefore, an amlodipine
formulation composed of only (S)-amlodipine has been
developed [16]. (S)-amlodipine is in use in many Asian,
African, Latin American and Commonwealth of Inde-
pendent States (CIS) countries. The standard dose of
(S)-amlodipine recommended is half that of racemic
amlodipine.
Although few published studies including a meta ana-
lysis [17] indicated that (S)-amlodipine and racemic
amlodipine show similar efficacy and safety [18, 19], data
from a post marketing study involving over 5000 pa-
tients has shown that the incidence of leg edema with
(S)-amlodipine is as low as 1.56 % overall [20]. Also, (S)-
amlodipine has been recommended as an ideal therapy
for switching from conventional racemic amlodipine for
patients developing peripheral edema [21].
Although several clinical trials comparing amlodipine
and (S)-amlodipine have been done, no adequately
powered, properly conducted, randomised controlled
clinical trial has compared the incidence of leg edema as
a primary outcome between the two drugs. The influence
of (S)-amlodipine compared to racemic amlodipine on
edema incidence in patients on CCB, beta blocker (BB)
and Angiotensin Converting Enzyme Inhibitor (ACEI)/
Angiotensin Receptor Blocker (ARB) triple therapy has
also not been assessed in a clinical trial.
Therefore the objective of this study was to assess and
compare the antihypertensive efficacy and incidence of
leg edema as a primary outcome, between (S)-amlodi-
pine and racemic amlodipine in the majority of patients
with essential hypertension, not controlled on a BB and
an ACEI/ARB in a tertiary care referral centre.
Methods
Trial design
This study was a prospective, randomized, double-blind,
double-dummy, comparative, parallel-group clinical trial
with an allocation ratio of 1:1. The Ethics Review
Committee, Faculty of Medicine, University of Colombo
(EC-10-014) approved the study protocol. The Cosmetics
Devices and Drugs Authority (CDDA) of Ministry of
Health, Sri Lanka gave the regulatory approval for the
conduct of the trial and for import of study medication, as
(S)-amlodipine is not a registered product in Sri Lanka.
The study was registered at the Clinical Trials Registry
of the Sri Lanka Medical Association, a publicly
accessed clinical trials registry recognised by the
WHO, (www.slctr.lk, SLCTR/2013/006). The study was
conducted in accordance with Good Clinical Practice
(GCP) guidelines.
Participants
Subjects visiting the Out Patient Department (OPD) for
treatment of hypertension at Institute of Cardiology
National Hospital of Sri Lanka, Colombo were enrolled
in the study. Male and female subjects with essential
hypertension taking a BB and ACEI/ARB, not responding
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to therapy (BP ≥140/90 mmHg) were included. All sub-
jects provided written informed consent.
Inclusion criteria were subjects between 30–64 years
of age who had essential hypertension and on stable
dose of BB and ACEI/ARB for at least 4 weeks, having
either systolic BP (SBP) ≥140 mmHg or diastolic BP
(DBP) ≥90 mmHg, or both, in sitting position.
Subjects sensitive to amlodipine, CCB or to any of the
ingredients of the test/reference product, taking CCB or
any antihypertensive therapy other than beta blocker
and ACEI/ARB, those with history of secondary, resistant
or malignant hypertension, myocardial infarction, percu-
taneous trans coronary angiogram (PTCA), coronary ar-
tery bypass grafting (CABG), cerebrovascular accident, or
transient ischemic attack (TIA) in last 6 months were
excluded. Patients with clinical diagnosis of congestive
cardiac failure, cardiac arrhythmias, any other abnor-
mality on ECG, known significant respiratory, liver, kidney,
neurological diseases, coagulation disorders, metabolic or
endocrinal disorder (except type 2 diabetes mellitus),
uncontrolled diabetes mellitus or type 2 diabetes melli-
tus taking insulin or oral hypoglycemic drugs other
than metformin or sulfonylurea and more than one sul-
fonylurea were also excluded. Pregnant and lactating
women or the women in the reproductive age group
not practicing the effective means of contraception, pa-
tients with known alcohol or drug abuse and any condi-
tion that, in the opinion of the investigator, does not
justify inclusion in the study were also excluded.
Interventions
The test medication used was tablets containing (S)-
amlodipine besylate 5 mg (high dose) and 2.5 mg (low
dose). The reference medication was amlodipine besylate
10 mg (high dose) and 5 mg (low dose). The starting dose
of conventional amlodipine was the usual maintenance
dose required by patients of 10 mg daily and corresponding
(S)-amlodipine dose of 5 mg daily. These starting doses
were down titrated to 5 mg conventional amlodipine and
2.5 mg (S)-amlodipine by the investigators if BP was con-
sidered too low (<115/75 mmHg) or patients was unable to
tolerate the dose or occurrence of any adverse events.
The tablets were dispensed in a sachet containing two
tablets. One of them was the test or reference medica-
tion and the other was a dummy tablet either for test or
reference medication and 1 month’s supply was issued.
Patient consumed the contents of one sachet (two tablets)
once a day, at the same time. Both test and reference
medication was given for 120 days.
Outcome variables
The primary outcome variable was the proportion of
patients having new peripheral edema (not present at
baseline), not attributable to any concomitant drug, as
assessed by clinical assessment of pitting edema at three
anatomical points on the body: 7 cm proximal to the
midpoint of the medial malleolus, behind medial malle-
olus and dorsum of the foot. This was compared against
baseline, at the end of therapy (120 days).
Antihypertensive efficacy was determined based on de-
crease in SBP, DBP and mean BP after each month of
therapy with the responder rate defined as subjects
showing reduction in SBP by ≥20 mmHg and or DBP by
≥10 mmHg or those achieving SBP ≤140 mmHg and
DBP ≤90 mmHg at end of therapy.
Secondary outcome variables were, change in the mag-
nitude of pitting edema scores (combined scores for all 3
points), difference in patient assessment questionnaire
after each month of therapy, percentage of the subjects
experiencing any drug related adverse events and the
change in investigational parameters between baseline
and after completion of therapy. There were no changes
to trial outcomes after the trial commencement. Subjects
were evaluated for efficacy and safety on day 30, day 60,
day 90 and day 120 of therapy.
BP measurement and laboratory tests
At each visit, arterial blood pressure was measured using
calibrated and validated digital BP apparatus with an ap-
propriate cuff size and a thermal printer (Omron 705CP
II upper arm blood pressure monitor with thermal
printer), recommended for the use in clinical trials, in
accordance with British Hypertension Society published
guidelines [22]. At each visit, after the patient had been
sitting for 5 min SBP and DBP were measured twice at
2-min intervals. The blood pressure recorded with the
thermal printer was taken and pasted on the case record
form (CRF).
Laboratory investigations were done in the laboratory
of the Department of Pharmacology, Faculty of Medicine,
University of Colombo on screening visit and day 120. On
the last visit, subject returned the empty sachets and un-
used medicines.
Assessment of ankle edema
Ankle edema was assessed using clinical assessment and
patient questionnaire. The clinical assessment method
was done using an adapted technique described for
evaluation of edema [23] and the scoring definitions
have been changed to identify both the depth of oedema
and recovery time of oedema. Pit depth was estimated
visually and score recorded and recovery time was given
in seconds as also described by Brodovicz et al. Edema
assessment was repeated at the three anatomical loca-
tions described earlier. The pit depth was estimated
visually and a score was given with 0 for no clinical
edema, 1 for slight pitting up to 2 mm depth with no
visible distortion and increasing in severity up to 4 for a
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very deep pit of 8 mm with gross distortion of extremity.
Pitting edema score was noted as the total score of all 3
points.
Patient-reported edema was recorded using a stan-
dardized and validated questionnaire. It included five
questions to assess the presence and severity of edema
as reported by patients, over the past week with the
highest score indicating maximum discomfort.
Adverse events were monitored in every clinic visit.
The investigators determined severity, causality and the
drug responsible for adverse event. Every adverse event
was reported in the CRF and all serious adverse events
were reported to the ethics committee and CDDA.
Sample size
Considering the average incidence of peripheral edema
with conventional amlodipine and (S)-Amlodipine to be
16 and 1.56 % respectively from previous studies [6, 20],
a sample size of 73 subjects in each group was found to
be sufficient to reveal this difference with 80 % power at
5 % significance level. A total of 200 subjects were
screened to randomise 172 subjects in to the study to
achieve sample size of 146 for analysis after allowing for
15 % dropouts. Interim analysis was not planned nor
done and there were no stopping guidelines.
Randomization procedure
The eligible subjects were randomized to test or refer-
ence groups according to the randomization schedule
generated by sponsor using online software available at
www.randomization.com, in blocks of 10. Randomization
chart was available with sponsor and trial site, which
was kept in a sealed envelope under lock and key to
conceal the allocation and the sealed envelope was
checked during monitoring visits. The investigators and
research assistants enrolled and assigned interventions
in a blinded manner, according to the predetermined
allocation sequence.
Blinding
This was a double-blind, double-dummy study with both
the subjects and investigators kept unaware of treatment
given. For blinding purposes, both formulations were
dispensed along with a dummy tablet identical to the
test or reference formulation by appearance, weight and
odor. The double-blinding was maintained throughout
the study.
Tests for compliance
Subjects returned the unused medications to the investi-
gators. Manual count of such returns were done and
recorded in the CRF. Failure of the patient to come for
follow-up was considered as failure of compliance.
Concomitant treatment
Enrolled subjects continued the BB and ACEI/ARB they
were taking prior to randomization. The dosage of these
drugs were not altered or modified. Additional antihy-
pertensive drugs were not added to the investigational
drug.
Statistical methods
Intension to treat analysis (ITT) for safety data and per
protocol analysis for efficacy data was performed. Mean
SBP, DBP and mean BP were calculated as mean ± standard
deviation (SD) and compared between the groups/baseline
values using t-test. Fischer’s exact test was applied to ob-
serve if there was significant difference between responder
rates and to observe if there were significant difference
between proportions of subjects having peripheral edema
not attributable to any concomitant drug. Changes in the
scores of pitting edema test and scores of patient assess-
ment questionnaire were compared between the groups
using Mann-Whitney test. Tolerability was assessed by
evaluating the proportion of patients reporting side effects
not attributed to any concomitant drug with the global as-
sessment of the subject or physician about the tolerability
and efficacy. Fischer’s exact test was applied to observe if
there was significant difference between the proportions.
Laboratory investigation values were calculated as
mean ± SD and compared between the groups or base-
line values using t-test. For all statistical tests, an over-
all p value of less than or equal to 0.05 was considered
as significant. The statistical analysis was performed
using Graph Pad InStat 3.00.
Results
Participants
Of the 172 patients randomized, 146 patients (amlodipine,
N= 76 and S-amlodipine, N= 70) completed 120 days of
the study duration (Fig. 1).
The baseline characteristics (age, weight, gender, con-
comitant illness and laboratory values) were comparable
between the 2 groups (Table 1). Mean age was 57 years
and majority were males in both groups. Although 41 %
in the (S)-amlodipine group and 34 % in the racemic
amlodipine group had type 2 diabetes mellitus, this dif-
ference was not statistically significant.
The other antihypertensives taken were captopril, biso-
prolol, enalapril, atenolol, carvedilol, losartan and meto-
prolol, with comparable distribution in both groups
(Table 1). Adherence to therapy was also equal between
the two groups as indicated by mean actual pill count
116.70 ± 3.24 vs 116.41 ± 3.28 and percentage pill count
of the ideal count 97.25 ± 2.70 % vs. 97.01 ± 2.74 % in
(S)-amlodipine and racemic amlodipine groups res-
pectively. After 90 days, most patients in both groups
were on lower dose with significantly more patients in
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the racemic amlodipine group on the lower strength of
the medication (80 % in racemic amlodipine and 61 %
in (S)-amlodipine; p = 0.0098).
Incidence of edema
The incidence of new edema any time after rando-
mization, was 31.40 % for test and 46.51 % for reference
(p = 0.0301); The absolute risk reduction (ARR) of new
edema was 15.1 % with relative risk reduction (RRR) of
32.47 % and number needed to treat (NNT) of seven. In
11 out of 27 (55 %) patients in S-amlodipine group the
edema resolved during the study, while edema resolution
was 17/40 (43.59 %) in racemic amlodipine group (p = ns).
After 120 days of therapy, pitting edema score in-
creased significantly in racemic amlodipine group com-
pared to (S)-amlodipine (p = 0.038) and increment of
score was highly significant (p < 0.0001) with amlodipine
compared with baseline value (Table 2). The temporal
relationship of edema indicates that most patients had
highest edema scores at 30 days in V1 in both groups
but edema scores reduced over the next 3 months
(Table 2). Patient assessment questionnaire for edema
score also followed somewhat similar pattern (Table 3).
In the racemic amlodipine group there were 26 males
(age: 57.42 ± 05.57 years), 14 females (age:58.57 ±
04.18 years) and in the (S)-amlodipine group 14 males
(age: 57.43 ± 04.67 years), 13 females (age: 57.46 ±
06.05 years) who developed edema. There was no sig-
nificant difference in the incidence of edema between
males and females in either group.
The mean age of patients having edema in test group
(N= 27) was 57.44 ± 05.27 and in reference group (N= 40)
was 57.83 ± 05.24. The mean age of patients not having
edema in test group (N= 59) was 56.10 ± 05.88 and in ref-
erence group (N= 46) was 56.11 ± 05.57. There was no
significant difference in the age of patients with edema or
without edema in each group.
Blood pressure control
The SBP and DBP and the mean BP decreased signifi-
cantly in both groups, without any significant difference
between groups by day 120 (Table 4). The lowest mean
blood pressure was recorded at 60 days in V3 and
Fig. 1 Consort diagram showing the flow of participants
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although the BP has increased slightly over the next 2
visits, the mean BP was significantly lower by the end of
the study in both arms (Table 4). The percentage of re-
sponders was 98.57 % in test and 98.68 % in reference
group (per protocol analysis, N= 146, p = ns; Table 5).
There was no difference in heart rate between the two
groups over time.
Safety
The global assessment for efficacy and tolerability to
treatment was similar in both the groups. The adverse
events with ITT analysis,(N = 172; Table 6) showed that
the most common adverse events were pitting edema
and increased urinary frequency (24.41 % in each group).
Other adverse events were headache, muscle cramps,
Table 1 Baseline characteristics (for completed patients, N = 146)
Parameter Test group Reference group p
Number of patients 70 76 na
Age in years; (mean ± SD) 56.46 ± 5.80 56.83 ± 5.57 ns
Weight; (kg) (mean ± SD) 63.82 ± 9.33 65.72 ± 11.94 ns
Male: Female 48:22 52:24 ns
Patients with type II diabetes; %, (n/N) 41.43, (29/70) 34.21, (26/76) ns
Patients with history of angina; %, (n/N) 5.71, (4/70) 2.63, (2/76) ns
Patients on captopril; %, (n/N) 32.85 % (23/70) 30.26 % (23/76) ns
Patients on enalapril; %, (n/N) 31.42 % (22/70) 31.57 % (24/76) ns
Patients on losartan;%, (n/N) 34.28 % (24/70) 38.15 % (29/76) ns
Patients on atenolol; %, (n/N) 67.14 % (47/70) 63.15 % (48/76) ns
Patients on carvedilol; %, (n/N) 14.28 % (10/70) 25 % (19/76) ns
Patients on metoprolol;%, (n/N) 11.42 % (8/70) 7.89 % (6/76) ns
Patients on bisoprolol; %, (n/N) 4.28 % (3/70) 2.63 % (2/76) ns
Hb (mean ± SD) 13.61 ± 1.73 13.57 ± 1.55 ns
Total WBC count (mean ± SD) 7.67 ± 1.95 7.52 ± 1.91 ns
SGOT (mean ± SD) 32.94 ± 13.45 35.41 ± 19.20 ns
SGPT (mean ± SD) 35.86 ± 18.29 34.95 ± 20.79 ns
LDL (mean ± SD) 82.38 ± 26.83 77.26 ± 31.24 ns
HDL (mean ± SD) 40.24 ± 9.18 38.26 ± 8.19 ns
VLDL (mean ± SD) 29.29 ± 11.70 34.13 ± 22.02 ns
Total cholesterol (mean ± SD) 152.17 ± 33.59 150.28 ± 39.42 ns
Triglycerides (mean ± SD) 146.24 ± 58.34 158.25 ± 76.50 ns
Fasting blood glucose (mean ± SD) 116.57 ± 43.35 120.09 ± 52.84 ns
Serum creatinine (mean ± SD) 0.90 ± 0.31 0.87 ± 0.25 ns
N total number of patients, n number of patients with the variable, SD standard deviation, na value not assessed, COPD chronic obstructive pulmonary disease, ns value
not statistically significant with p > 0.05; Mann-Whitney test was applied for continuous variables and Fisher’s Exact test was applied for categorical variables
Table 2 Evaluation of pitting edema score (ITT analysis, N = 172)
Variable Test group Reference group p*
N Pitting edema score (mean ± sd) N Pitting edema score (mean ± sd)
Baseline (day 0), V1 86 00.00 ± 00.00 86 0.05 ± 00.34 na
After 30 days of therapy, V2 86 01.09 ± 02.47 86 00.97 ± 01.88 ns
After 60 days of therapy, V3 86 00.44 ± 01.36 86 00.88 ± 01.88 ns
After 90 days of therapy, V4 86 00.38 ± 01.21 86 00.73 ± 01.66 ns
After 120 days of therapy, V5 86 0.33 ± 01.00 86 00.83 ± 01.52 0.0380
p** na <0.0001
ITT intention to treat, N number of patients, V1-V5 Visits 1–5, na not applicable, ns not significant
Mann-Whitney test was applied; *p value, when compared between the groups; **p value, when V5 value compared with baseline value in same group;
p <0.05 = statistically significant
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constipation, peri-orbital edema, vertigo, dizziness, and
rash. No difference was observed in adverse events in
the two groups. There were two serious adverse events
(SAE) reported. One death occurred in a patient ran-
domized to test group after 15 days of randomization;
the cause of death was acute myocardial infarction, and
this SAE was considered unrelated to the study drug. A
patient who was hospitalized due to vasculitic rash on
lower limbs in reference group was the other SAE. This
was also considered unrelated to the study treatment.
There were no clinically significant differences in the
biochemical parameters, urinary and electrocardiographic
tests before and after treatments.
Discussion
This is probably the first adequately powered rando-
mised controlled clinical trial, evaluating leg edema as a
primary outcome which recruited both men and women,
comparing efficacy and safety of (S)-amlodipine vs ra-
cemic amlodipine. CCBs are associated with a consider-
able risk of peripheral oedema [5, 6, 13, 24, 25], that
may reduce patient compliance or necessitate switching
to a different drug [26]. This study shows that signifi-
cantly high percentage (46.5 %) of patients developed
peripheral edema while on racemic amlodipine com-
pared to the percentage developing edema with (S)-
amlodipine (31.4 %). The difference in the two groups is
significant and represents a RRR of approximately 33 %
with a NNT of only seven.
These results are in contrast to a systematic review
and meta analysis of the clinical trials comparing (S)-
amlodipine and racemic amlodipine [17] which did not
show any significant difference in incidence of edema
when only high-quality trials were included, although
when all the trials were considered, the edema incidence
was significantly less with (S)-amlodipine compared to
racemic amlodipine.
The edema incidence in our trial was much higher
than most of the previously reported incidence with ra-
cemic amlodipine at the doses used, varying from 2 to
32 % [5, 6, 18, 24]. The main reason for this high inci-
dence is probably active surveillance for edema in this
trial both by patient assessment questionnaire for edema
and objective assessment by investigators using an
edema score. It is noted that considerably higher rates of
adverse events are reported by active surveillance sys-
tems when compared with passive systems [27]. Rates
of edema reported in clinical trials involving CCBs
may have been affected by active or passive surveil-
lance for edema, which could have given the wide
variation in the reported edema incidence in the pa-
tients given CCB [28–30].
Table 3 Evaluation of patient assessment questionnaire for edema (ITT analysis, N = 172)
Variable Test group Reference group p*
N Patient questionnaire score (mean ± sd) N Patient questionnaire score (mean ± sd)
Baseline (day 0), V1 86 00.00 ± 00.00 86 00.14 ± 01.02 na
After 30 days of therapy, V2 86 02.34 ± 05.23 86 02.07 ± 04.31 ns
After 60 days of therapy, V3 86 01.03 ± 03.34 86 02.29 ± 04.60 ns
After 90 days of therapy, V4 86 01.06 ± 03.41 86 01.81 ± 04.02 ns
After 120 days of therapy, V5 86 01.11 ± 03.35 86 02.60 ± 04.50 0.0363
p** na <0.0001
ITT intention to treat, N number of patients, V1-V5 visits 1–5, na not applicable, ns not significant
Mann-Whitney test was applied; *p value, when compared between the groups; **p value, when V5 value compared with baseline value in same group;
p <0.05 = statistically significant
Table 4 Evaluation of mean blood pressure at baseline and after therapy (PP analysis; N = 146)
Variable Test group Reference group p *
N mm of Hg (mean ± SD) N mm of Hg (mean ± SD)
Baseline (day 0), V1 70 113.01 ± 25.93 76 113.99 ± 12.17 ns
After 30 days of therapy, V2 70 101.08 ± 17.92 76 95.33 ± 12.34 ns
After 60 days of therapy, V3 70 90.08 ± 06.01 76 89.81 ± 8.02 ns
After 90 days of therapy, V4 70 102.50 ± 14.34 76 99.01 ± 08.45 ns
After 120 days of therapy, V5 70 94.42 ± 17.25 76 95.89 ± 03.34 ns
p** <0.0001 <0.0001
PP per protocol, N number of patients, SD standard deviation, ns not significant
Paired t test was applied; *p value, when compared between the groups; **p value, when V5 value compared with baseline value in same group;
p <0.05 = statistically significant
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Higher edema scores by patients is likely to result in
higher degree of discomfort for many patients [31].
Therefore in populations that experience a high incidence
of edema with racemic amlodipine, use of chirally pure
(S)-amlodipine would be advantageous due to lower inci-
dence of edema which could result in improved adherence
to therapy and hence blood pressure control.
The cause of CCB-induced edema is elevated capillary
hydrostatic pressure. This results from preferential dila-
tion of pre-capillary vessels. Renin-angiotensin system
(RAS) blockers such as ACEIs and ARBs normalize
hydrostatic pressure by causing post-capillary dilation.
Therefore they could be used for prevention or reversal
of CCB-induced edema [11].
Several clinical trials have shown that the incidence of
oedema is lower in patients who receive ACEI/CCB or
ARB/CCB combination therapy when compared to those
treated with CCB therapy alone. [17, 28, 32] A meta-
analysis that included 82 studies that compared the
safety and efficacy of ACEI/CCB therapy against nine
monotherapy regimens stated that this drug combin-
ation was associated with a lower rate of side effects
[33]. It was also noted that the side effects led to with-
drawal of amlodipine or nifedipine monotherapy [33]. In
our study as both arms received beta-blockers and ACE-
I/ARBs, the contribution of these medications to edema
can be assumed to be equal in both the groups. The in-
cidence of leg edema could have been higher in both
groups if the patients were not on concomitant ACEI/
ARBs. As the cause of oedema is pre capillary vasodilata-
tion, higher rates of oedema associated with CCBs may
be occurring more in tropical countries due to the warm
environment resulting in vasodilatation in peripheries.
The reported rates of edema with CCBs seem to be
higher in tropical countries with warm environments
such as India and Brazil [19, 21, 34] while the rates seem
lower in countries with average lower temperatures such
as USA and Korea [18, 28]. Although there are no stud-
ies supporting this theory in literature, seasonal variation
in incidence of edema has been reported [5] and authors
have observed patients reporting resolution of edema on
visiting cold climates and reappearance of edema when
returning to warm environments.
In this trial both arms received triple therapy with a
CCB, ACEI/ARB and a BB and excellent blood pressure
control was achieved in 98 % of patients. Multiple trials
have previously reported that there are highly significant
cardiovascular outcome benefits of antihypertensives
given in combination [35] and the use of combination
therapy in our study population is consistent with the
recommendations of Eighth Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC8) [36]. Cur-
rently amlodipine is one of the most efficacious drugs
recommended for triple therapy in uncontrolled hyper-
tension [37], and this study also confirms that. We ob-
served that most patients needed only a low dose of
amlodipine to control the blood pressure in each arm
with triple therapy with the percentage of patients down
titrated to low dose significantly higher in the racemic
amlodipine group (80 %) compared to the percentage in
(S)-amlodipine group (61 %). The temporal relationship
of edema showed higher edema scores at 30 and 60 days
Table 5 Percentages of blood pressure responders at 120 days
(PP analysis; N = 146)
Drug Responders p
Test group %, (n/N) 98.57, (69/70) ns
Reference group %, (N) 98.68, (75/76)
N total number of patients, n number of responders, Fisher’s Exact test was
applied; p <0.05 = statistically significant, ns not significant, PP per protocol
Responders: Subjects showing reduction in systolic blood pressure by
≥20 mmHg and / or diastolic blood pressure by ≥10 mm or those achieving
systolic blood pressure ≤140 mmHg and diastolic blood pressure
≤90 mm of Hg
Table 6 Adverse events (Intention to treat analysis, N = 172)
Adverse events Test group %, (n/N) Reference group %, (n/N) P
Pitting edema 31.40, (27/86) 46.51, (40/86) 0.0301
Increased urinary frequency 24.41, (21/86) 24.41, (21/86) ns
Muscle cramps 4.65, (4/86) 2.32, (2/86) ns
Rash on face/arms 2.32, (2/86) 0 (0/86) ns
Headache 2.32, (2/86) 3.48, (3/86) ns
Constipation 1.16, (1/86) 2.32 (2/86) ns
Peri-orbital edema 1.16, (1/86) 0 (0/86) ns
Vertigo & dizziness 0 (0/86) 1.16, (1/86) ns
Vasculitic rash on lower limbs 0 (0/86) 1.16, (1/86) ns
Death 1.16, (1/86) 0 (0/86) ns
Total no. of AEs 68.60, (59/86) 81.39, (70/86) 0.03
AE adverse event, N total number of patients, n number of AEs, Fisher’s exact test was applied. p < 0.05 = statistically significant, ns value not significant
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and resolution thereafter in both groups but mainly in
(S)-amlodipine group over the next 2–3 months (Tables 2
and 3). This could probably be explained by the higher
doses used initially in this trial in both arms with subse-
quent down titration of doses. It is well known that
edema with CCB occurs in a dose dependent manner
[5]. Other reasons such as postural effects due to the ad-
vice given to patients when they developed edema may
also have contributed to resolution of edema. Edema
score increasing initially with subsequent resolution is
also supported by lowest mean BP recorded at 60 days
(Table 4) with subsequent slight increment of BP noted,
which again probably occurred due to down titration of
drug doses.
Adverse events, in particular leg edema with amlodi-
pine has been reported to occur more in female patients
in some studies [1, 6, 38]. Another study among female
Korean patients with mild to moderate hypertension,
quantified pedal edema during treatment with (S)-Amlo-
dipine nicotinate versus amlodipine besylate [38] and
concluded that females had a reduced level of ankle
edema, with no significant difference in antihypertensive
efficacy. Thus it is important to note that our study did
not show any significant difference in incidence of
edema between males and females. There was also no
significant difference between the ages of the patients
who developed edema compared to those who did not
develop edema in both groups although some studies re-
port edema occurrence with advancing age [5].
Notable amongst the other adverse events, was the
high incidence of frequent urination, noted in almost
25 % in both the groups. Amlodipine is known to have
natriuretic effect [39] although reported frequency is less
than 1 % according to the prescribing information for
amlodipine besylate tablets. However there are previous
studies reporting higher incidence of increased urinary
frequency [40].
The natriuretic effect of CCBs augments the antihyper-
tensive effect of ACEIs [41, 42] and this better antihyper-
tensive efficacy in combination is another advantage cited
for combining CCBs with RAS inhibitors such as ACEI/
ARBs in addition to mitigating edema due to CCB [13, 34].
Muscle cramps, headache and constipation were re-
ported by 1–5 % of patients in both groups which are
well recognised side effects of CCBs and incidence of
these side effects were not significantly different in both
groups and from previous reports.
Conclusion
The current recommendation in most hypertension
treatment guidelines [43], is combination antihyperten-
sive therapy for patients whose BP is 20 mm Hg above
the systolic goal or 10 mmHg above the diastolic goal,
which were the inclusion criteria for BP this clinical trial.
This study which randomised patients with inadequately
controlled BP on ACEI/ARB and BB to compare the effi-
cacy and safety of (S)-amlodipine and racemic amlodi-
pine, with new onset leg edema as a primary outcome,
showed significantly reduced incidence of edema with
(S)-amlodipine compared to racemic amlodipine with
excellent blood pressure control in both arms. As develop-
ment of edema with CCB results in poor adherence, poor
BP control and necessitate switching therapy, using (S)-
amlodipine is likely to result in better tolerance and BP
control. This is particularly so when used in combination
therapy for control of hypertension, especially in popula-
tions that experience high rates of edema with CCB.
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